AU2009312355C1 - Oxidized lipid compounds and uses thereof - Google Patents

Oxidized lipid compounds and uses thereof Download PDF

Info

Publication number
AU2009312355C1
AU2009312355C1 AU2009312355A AU2009312355A AU2009312355C1 AU 2009312355 C1 AU2009312355 C1 AU 2009312355C1 AU 2009312355 A AU2009312355 A AU 2009312355A AU 2009312355 A AU2009312355 A AU 2009312355A AU 2009312355 C1 AU2009312355 C1 AU 2009312355C1
Authority
AU
Australia
Prior art keywords
disease
disorder
carboxy
inflammatory
glycero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009312355A
Other languages
English (en)
Other versions
AU2009312355A2 (en
AU2009312355B2 (en
AU2009312355A1 (en
Inventor
Eyal Breitbart
Erez Feige
Gideon Halperin
Eti Kovalevski-Ishai
Itzhak Mendel
Niva Yacov
Zeev Ziniuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of AU2009312355A1 publication Critical patent/AU2009312355A1/en
Publication of AU2009312355A2 publication Critical patent/AU2009312355A2/en
Application granted granted Critical
Publication of AU2009312355B2 publication Critical patent/AU2009312355B2/en
Publication of AU2009312355C1 publication Critical patent/AU2009312355C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/26—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-nitrogen bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4411—Amides of acyclic unsaturated acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
AU2009312355A 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof Ceased AU2009312355C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19322008P 2008-11-06 2008-11-06
US61/193,220 2008-11-06
PCT/IL2009/001049 WO2010052718A1 (en) 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof

Publications (4)

Publication Number Publication Date
AU2009312355A1 AU2009312355A1 (en) 2010-05-14
AU2009312355A2 AU2009312355A2 (en) 2011-05-12
AU2009312355B2 AU2009312355B2 (en) 2015-08-27
AU2009312355C1 true AU2009312355C1 (en) 2016-02-18

Family

ID=42152558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009312355A Ceased AU2009312355C1 (en) 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof

Country Status (14)

Country Link
US (2) US9206206B2 (enExample)
EP (3) EP2826369A3 (enExample)
JP (2) JP5752599B2 (enExample)
KR (1) KR20110095288A (enExample)
CN (2) CN104788492A (enExample)
AU (1) AU2009312355C1 (enExample)
CA (1) CA2740726A1 (enExample)
ES (1) ES2534044T3 (enExample)
HK (2) HK1206199A1 (enExample)
MX (1) MX2011004773A (enExample)
NZ (1) NZ592357A (enExample)
RU (2) RU2532546C2 (enExample)
WO (1) WO2010052718A1 (enExample)
ZA (1) ZA201102872B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
WO2012119781A2 (en) * 2011-03-10 2012-09-13 University Of Geneva Novel lipids, phospholipids, phospholipid and lipid compositions and their use
JP6109175B2 (ja) * 2011-09-01 2017-04-05 バスキュラー バイオジェニックス リミテッド 酸化リン脂質の製剤および剤形
WO2013088245A1 (en) * 2011-12-12 2013-06-20 Vascular Biogenics Ltd. Treatment of inflammation
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US9771385B2 (en) * 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3328401B1 (en) * 2015-07-31 2020-10-14 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
AU2016303472B2 (en) 2015-07-31 2020-08-27 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2 and inflammation
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物
WO2021199003A1 (en) * 2020-04-02 2021-10-07 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of inflammation or infectious disease caused by coronavirus infection
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
JP2023547026A (ja) 2020-09-10 2023-11-09 バスキュラー バイオジェニックス リミテッド 運動精子ドメイン含有タンパク質２抗体およびその使用法
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
EP4499655A1 (en) * 2022-03-28 2025-02-05 F. Hoffmann-La Roche AG Synthesis of isomerically pure polyol-based phosphoramidites

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
US20070112200A1 (en) * 2001-02-27 2007-05-17 Trustees Of Tufts College Non-racemic hexafluoreleucine,and methods of making and using it

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638578B2 (enExample) 1973-05-18 1981-09-08
US4166132A (en) 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
JPS5993022A (ja) * 1982-11-16 1984-05-29 Kao Corp ポリオ−ルエ−テル化合物およびその製造法ならびにこれを含有する化粧料
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) * 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
DE3663522D1 (en) * 1985-11-29 1989-06-29 Takeda Chemical Industries Ltd Phospholipid derivatives, their production and use
US5061626A (en) * 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
JPH01502022A (ja) * 1986-04-07 1989-07-13 ジ・アップジョン・カンパニー 駆虫薬第４級アルキルアシルヒドラゾン、使用方法および組成物
JPS6294A (ja) 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
AU614636B2 (en) * 1988-07-21 1991-09-05 Ciba Specialty Chemicals Holding Inc. Corrosion inhibition
JPH0248585A (ja) 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JP3128782B2 (ja) * 1992-06-12 2001-01-29 科学技術振興事業団 架橋高分子薄膜の製造方法
US5561052A (en) * 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
WO1995023592A1 (en) 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (ja) 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
JPH0859545A (ja) * 1994-08-24 1996-03-05 Kao Corp カルボキシエチルエーテル誘導体及びこれを含有する洗浄剤組成物
EP0781138B1 (en) * 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
DE19547022A1 (de) * 1995-12-15 1997-06-19 Boehringer Mannheim Gmbh Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
JP3781877B2 (ja) 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
US6414168B1 (en) * 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
ATE287700T1 (de) 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
ATE306563T1 (de) 2000-03-31 2005-10-15 Univ California Funktionaler nachweis von lipoprotein mit hoher dichte
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
MXPA03004517A (es) 2000-11-24 2004-03-26 Vascular Biogenics Ltd Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.
JP4191997B2 (ja) 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
CN1526605A (zh) * 2003-09-23 2004-09-08 陈东明 一种水上游泳池
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US20060194765A1 (en) * 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US8252775B2 (en) * 2005-07-21 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Method of treating multiple sclerosis with phosphocholine containing lipids
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JP2008037763A (ja) * 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US9006217B2 (en) * 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) * 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
CN101877963A (zh) * 2007-11-28 2010-11-03 泰华制药工业有限公司 延缓临床确诊的多发性硬化症发作的方法
US8999960B2 (en) * 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
JP5752599B2 (ja) * 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
KR101810257B1 (ko) 2010-01-05 2017-12-18 바스큘라 바이오제닉스 리미티드 아교모세포종 ｇｂｍ을 치료하기 위한 조성물 및 방법
WO2011083465A1 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201
JP6109175B2 (ja) 2011-09-01 2017-04-05 バスキュラー バイオジェニックス リミテッド 酸化リン脂質の製剤および剤形

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112200A1 (en) * 2001-02-27 2007-05-17 Trustees Of Tufts College Non-racemic hexafluoreleucine,and methods of making and using it
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids

Also Published As

Publication number Publication date
EP2348866B1 (en) 2015-01-07
US20130203707A1 (en) 2013-08-08
JP5752599B2 (ja) 2015-07-22
JP2015129157A (ja) 2015-07-16
CN102271517A (zh) 2011-12-07
MX2011004773A (es) 2011-06-21
RU2014136085A (ru) 2016-03-27
HK1206198A1 (en) 2016-01-08
RU2011122729A (ru) 2012-12-20
ZA201102872B (en) 2013-01-30
EP2348866A1 (en) 2011-08-03
EP2348866A4 (en) 2012-04-11
EP2826370A2 (en) 2015-01-21
CA2740726A1 (en) 2010-05-14
WO2010052718A9 (en) 2011-06-16
WO2010052718A1 (en) 2010-05-14
EP2826369A3 (en) 2015-03-18
EP2826369A2 (en) 2015-01-21
NZ592357A (en) 2013-09-27
ES2534044T3 (es) 2015-04-16
RU2532546C2 (ru) 2014-11-10
HK1155906A1 (en) 2012-06-01
US20110207703A1 (en) 2011-08-25
JP2012507577A (ja) 2012-03-29
AU2009312355A2 (en) 2011-05-12
HK1206199A1 (en) 2016-01-08
AU2009312355B2 (en) 2015-08-27
CN104788492A (zh) 2015-07-22
KR20110095288A (ko) 2011-08-24
EP2826370A3 (en) 2015-04-08
CN102271517B (zh) 2015-04-08
AU2009312355A1 (en) 2010-05-14
US9206206B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
AU2009312355B2 (en) Oxidized lipid compounds and uses thereof
US8999960B2 (en) Oxidized thiophospholipid compounds and uses thereof
EP1626728B1 (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
RU2509071C2 (ru) Новые липидные соединения
US8759557B2 (en) Process for the preparation of oxidized phospholipids
CN102369193A (zh) 缩醛磷脂化合物、包含缩醛磷脂化合物的药物组合物和用于治疗衰老性疾病的方法
KR20090112631A (ko) 오메가-3 지질 화합물
CA3055464A1 (en) Acefapc for the treatment of acetylcholine-dependent diseases
JPH041759B2 (enExample)
HK1155906B (en) Oxidized lipid compounds and uses thereof
HK1088234B (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
EP0185589A1 (fr) Nouveaux dérivés de l'acide méthylène bis-phosphonique, leur préparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 APR 2011 AND 28 APRIL

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 NOV 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 NOV 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired